ASCO 2011

Phase 4 Trial to Compare Efficacy, Tolerability of Temsirolimus With and Without Elevated Starting Dose in Mantle Cell Lymphoma

A Phase 3 study of temsirolimus showed significantly longer progression-free survival in patients with relapsed, refractory mantle cell lymphoma. Investigators now want to determine if that efficacy can be maintained by eliminating the original elevated starting dose associated with a high incidence of adverse events, according to information presented at the American Society of Clinical Oncology’s 2011 Annual Meeting.

Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer

Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology’s 2011 Annual Meeting.

ICON7 Trial Shows Bevacizumab Increases Survival in Women with Newly Diagnosed Ovarian Cancer

The addition of bevacizumab to carboplatin and paclitaxel chemotherapy for the first-line treatment of women with ovarian cancer may offer benefit compared with standard chemotherapy alone, particularly for patients with more aggressive disease, investigators noted in a presentation during the American Society of Clinical Oncology’s 2011 Annual Meeting.

Oxaliplatin + Doxorubicin in Recurrent Ovarian Cancer Shows Promise, Tolerability

The combination of oxaliplatin and doxorubicin showed promising efficacy in either platinum-sensitive or platinum-resistant recurrent ovarian cancer, as reported by Ilya Pokateav, MD, from the Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, and colleagues at the American Society of Clinical Oncology’s 2011 Annual Meeting.

Sunitinib Treatment, Activity Shows No Negative Post-Treatment Effect in mRCC Patients with Previous Sunitinib or Interferon Alfa

Sunitinib reduces tumor growth while being administered, improves overall survival, and appears unlikely to alter tumor biology after treatment discontinuation according to Krastav Blagoev, MD, from the National Science Foundation, Arlington, VA, and colleagues, who presented study data at the American Society of Clinical Oncology’s 2011 Annual Meeting.